多发性骨髓瘤患者骨髓细胞中CD269、CD317的表达及其意义

Abstract
Figure/Table
References (21)
Related Citation (2)

Download: PDF (645 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expression and significance of CD269, CD317 in bone marrow cells of patients with multiple myeloma(MM). Methods A total of 86 patients with MM who were treated in Yuebei People′s Hospital of Guangdong province from January 2016 to May 2018 were selected as the observation group, another 80 patients with iron deficiency anemia during the same period were selected as the control group. The relative expressions of CD269 and CD317 in bone marrow cells, the levels of hemoglobin (HB), β2-microglobulin (β2-MG) and lactate dehydrogenase (LDH) were compared between the two groups, the relative expressions of CD269 and CD317 in different age and sex of the observation group were compared too. The correlations between the relative expressions of CD269, CD317 and the levels of HB, β2-MG and LDH were analyzed. Results The relative expressions of CD269 and CD317 in bone marrow cells in the observation group were significantly higher than that of the control group (P < 0.05). The levels of HB and β2-MG in the observation group were significantly lower than that in the control group (P < 0.05), but there was no significant difference in the level of LDH between the two groups (P > 0.05). There was no significant difference in the relative expressions of CD269 and CD317 in different age and sex of the observation group (all P > 0.05). According to Pearson correlation analysis, the results indicated that the relative expressions of CD269 and CD317 in bone marrow cells were negatively correlated with HB, β2-MG (P < 0.05), but there was no significant correlation with LDH (P > 0.05). Conclusion The expressions of CD269, CD317 in bone marrow cells of patients with MM are significantly elevated, while the levels of HB and β2-MG are significantly decreased. The relative expression of CD269 and CD317 are negatively correlated with HB and β2-MG respectively. Clinically, the expression of these four indicators can be further monitored to provide more comprehensive feedback on the actual condition of MM patients.

Key words： Multiple myeloma Bone marrow cell CD269 CD317

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Yali1 MA Zhanzhong2 HUANG Gang1 XIE Zhijun1 YANG Liping1

Cite this article:

HUANG Yali1 MA Zhanzhong2 HUANG Gang1 XIE Zhijun1 YANG Liping1. Expression and significance of CD269, CD317 in bone marrow cells of patients with multiple myeloma[J]. 中国医药导报, 2019, 16(13): 103-106.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I13/103

[1] 杨阳.补肾强骨方治疗多发性骨髓瘤的临床效果[J].临床医学研究与实践，2018，3（2）：120-121.
[2] 赵玲俊，高松，李晓.沙利度胺对多发性骨髓瘤患者外周血Th17与Treg细胞比值及IL-17、IL-35表达水平的影响[J].中国实验血液学杂志，2018，26（1）：187-191.
[3] 黄琦，沙辉，陈龙，等.多发性骨髓瘤和慢性淋巴细胞白血病患者血浆lncRNA MALAT1、LincRNA-p21和GAS5的表达水平及其诊断意义[J].吉林大学学报：医学版，2018，44（2）：339-345.
[4] 陈曦，蔡真.疫苗治疗多发性骨髓瘤的研究进展[J].中国肿瘤生物治疗杂志，2017，24（3）：311-316.
[5] 朱婕，张磊，张葆康，等.多发性骨髓瘤患者血清IL-6、IL-6R、MCL1的检测分析及与预后的关系[J].检验医学与临床，2018，15（6）：792-794.
[6] 陈颖，杨清.多发性骨髓瘤SET结构域蛋白相关靶向药物抗肿瘤作用机制的研究进展[J].现代药物与临床，2018，33（4）：997-1001.
[7] 中国医师协会血液科医师分会，中华医学会血液学分会，中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南（2015年修订）[J].中华内科杂志，2015，54（12）：1066-1070.
[8] Okazuka K，Ishida T，Sato K，et al. Carfilzomib，lenalidomide，and dexamethasone therapy for refractory and relapsed multiple myeloma：a single-center study of 29 patients [J]. Rinsho Ketsueki，2018，59（6）：698-700.
[9] 林凡莉，周俊，叶丽，等.SDF-1、CXCR4表达及MVD与多发性骨髓瘤预后的关系[J].肿瘤，2017，37（11）：1179-1187.
[10] 赵继伟，洪少杰.57例中青年多发性骨髓瘤的临床特点[J].现代医院，2018，18（2）：264-267.
[11] 刘玉霞，胡国瑜，袁朝晖，等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志，2018，33（2）：58-61.
[12] Frigyesi I，Adolfsson J，Ali M，et al. Robust isolation of malignant plasma cells in multiple myeloma [J]. Blood，2014，123（9）：1336-1340.
[13] 袁青，陈绍水.循环微小RNA在多发性骨髓瘤中的应用[J].国际肿瘤学杂志，2018，45（1）：53-55.
[14] Staudinger M，Glorius P，Burger R，et al. The novel immunotoxin HM1.24-ETA′ induces apoptosis in multiple myeloma cells [J]. Blood Cancer J，2014，13（4）：219-220.
[15] 谭奎，沈婵娟，张玲，等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志，2017，32（6）：64-66.
[16] 周惠玉，孙伟才，张福军，等.β2-MG、Cys-C、uNGAL、uMA、uCr、uMA/Cr检测对多发性骨髓瘤早期肾功能损害的诊断价值[J].国际医药卫生导报，2018，24（2）：181-184.
[17] Chen KH，Wada M，Pinz KG，et al. A compound chimeric antigen receptor strategy for targeting multiple myeloma [J]. Leukemia，2018，32（2）：402-412.
[18] Harada T，Ozaki S. Targeted therapy for HM1.24 （CD317） on multiple myeloma cells [J]. Biomed Res Int，2014，1（2014）：965 384-965 385.
[19] 纪伟，吴洪坤，周琳，等.多发性骨髓瘤非编码RNA的研究进展[J].检验医学，2018，33（3）：264-268.
[20] Ishiguro T，Kawai S，Habu K，et al. A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients [J]. Cancer Sci，2010， 101（10）：2227-2233.
[21] 吴迪，余艳丽，刘芳，等.多发性骨髓瘤伴非骨旁髓外病变临床分析[J].现代肿瘤医学，2018，26（4）：591-594.